Very interesting indeed.
Although my understanding is that the CD8 T-cells struggle to eliminate coxsackievirus B-infected cells, because coxsackievirus B uses cunning immune evasion techniques to make the cells it infects "invisible" to CD8 T-cell surveillance. CVB does this by removing the MHC-I receptors from the infected cell's surface, and this receptor is critical for normal CD8 T-cell operation. More info in
this paper.
This is interesting to me. When I first began looking into my symptoms, I thought chronic EBV infection could be my issue, and found
this paper on cytotoxic T cell therapy for EBV. I ended up corresponding with one of the authors, who encouraged me to get an EBV PCR, which was negative, so I began looking elsewhere. I guess that if CVB infection is the problem, then T cell therapy could be something, but hadn't thought about it. Can anyone link me to the "T cell expansion findings of Mark Davis"?
Another thing for ya'll to look at: I'm currently watching the Biology 3310/4310 lectures from Columbia University (Virology 101), and in
lecture 5, at around the 1-hour mark, the professor (who is a poliovirus expert) mentions an antiviral drug which binds strongly to lipid receptors, blocking poliovirus from sensing a key trigger in its infectious cycle. The virus is unable to uncoat, so it can't release its genome. I looked into this because obviously poliovirus is an enterovirus, and found
this paper. The drug is called Disoxaril (W55717), but I don't think anybody uses it because, as Dr. Racaniello mentions in the lecture, antiviral resistance is a big concern with this compound. Any thoughts on this?